Publicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (20)

2024

  1. Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology

    Scientific Reports, Vol. 14, Núm. 1

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

  2. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy

    Cancers, Vol. 15, Núm. 24

2022

  1. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

    Journal of Thoracic Oncology, Vol. 17, Núm. 5, pp. 661-674

  2. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

  3. Future care for long-term cancer survivors: towards a new model

    Clinical and Translational Oncology, Vol. 24, Núm. 2, pp. 350-362

2021

  1. Impact of the COVID-19 pandemic on the care of cancer patients in Spain

    ESMO open, Vol. 6, Núm. 3, pp. 100157

  2. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888

  3. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

    Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1529-1541

  4. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

    Lung Cancer, Vol. 155, pp. 151-155

2020

  1. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

    Investigational New Drugs, Vol. 38, Núm. 2, pp. 457-467

  2. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

    BMC Psychology, Vol. 8, Núm. 1

  3. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2253-2263

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

  2. Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH

    Clinical and Translational Oncology, Vol. 20, Núm. 4, pp. 443-447

  3. Proposal of the SEOM, SEAP and SEFH for the creation of a National Strategy for Precision Medicine in Cancer

    Revista Espanola de Patologia

2017

  1. Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: A position statement of SEOM, SEAP and SEFH

    Farmacia Hospitalaria, Vol. 41, Núm. 6, pp. 688-691

  2. Surgical treatment of low and intermediate grade lung net

    Journal of Thoracic Disease, Vol. 9, pp. S1435-S1441

2014

  1. Atypical carcinoid tumours of the lung: Prognostic factors and patterns of recurrence

    Thorax, Vol. 69, Núm. 7, pp. 648-653